The value of bladder cancer (BC) substaging into macroscopic (pT3b) and microscopic (pT3a) perivesical fat extension in lymph node (Ln)-negative patients is controversially discussed and limited evidence for prognostic relevance of additional histopathological factors in pT3 BC exists. We evaluated the prognostic value of pT3 substaging and established pathological and clinical parameters with focus on tumor invasive front (TIF) and tumor size.
Specimens of 52 patients treated with radical cystectomy (RC) for pT3 a/b muscle-invasive BC were reviewed and re-evaluated by a pathologist specialized in uropathology. Clinical variables and standard histopathologic characteristics were assessed including TIF and tumor size. Their value as prognosticators for overall survival (OS) and recurrence-free survival (RFS) was evaluated.
Mean age of patients was 67.55 years. Tumors were staged pT3a in 28 patients (53.8%) and pT3b in 24 (46.8%). Median OS was 34.51 months. Median tumor size was 3.2 cm, median TIF was 11.0 mm. Differences in OS between pT3a and pT3b were not significant (p = 0.45). Carcinoma in situ (CIS) and lymphovascular invasion (LVI) were significantly associated with pT3b tumors. Univariate analysis could not identify pathological prognosticators like TIF or tumor size for OS and RFS (p for all > 0.05).
No significant differences in OS or RFS were observed comparing Ln-negative pT3 BC following radical cystectomy. Additional pathologic variables like TIF could not be identified as prognosticator. Relevance of pT3 BC substaging needs reevaluation in larger prospective cohorts.
World journal of urology. 2021 Apr 21 [Epub ahead of print]
Moritz Maas, Johannes Mischinger, Eva Compérat, Marcus Scharpf, Falko Fend, Tilman Todenhöfer, Arnulf Stenzl, Georgios Gakis, Steffen Rausch
Department of Urology, University Hospital, Tübingen, Germany., Department of Urology, University Hospital, Graz, Austria., Department of Pathology, University Hospital, Wien, Austria., Department of Pathology, University Hospital, Tübingen, Germany., Clinical Trials Unit, Studienpraxis Urologie, Nürtingen, Germany., Department of Urology, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Germany. .